Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
0.4990
-0.0310 (-5.85%)
At close: May 1, 2025, 4:00 PM
0.4941
-0.0049 (-0.98%)
Pre-market: May 2, 2025, 6:09 AM EDT

Company Description

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.

The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.

Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia.

The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer.

It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Aptevo Therapeutics Inc.
Aptevo Therapeutics logo
Country United States
Founded 2016
Industry Biotechnology
Sector Healthcare
Employees 37
CEO Marvin White

Contact Details

Address:
2401 4th Avenue, Suite 1050
Seattle, Washington 98121
United States
Phone 206 838 0500
Website aptevotherapeutics.com

Stock Details

Ticker Symbol APVO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001671584
CUSIP Number 03835L207
ISIN Number US03835L2079
Employer ID 81-1567056
SIC Code 2834

Key Executives

Name Position
Marvin L. White President, Chief Executive Officer and Director
Jeffrey G. Lamothe CA Executive Vice President and Chief Operating Officer
SoYoung Kwon J.D., LL.M. Corporate Secretary, Senior Vice President, General Counsel, Business Development and Corporate Affairs
Dr. Dirk Huebner M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Apr 29, 2025 8-K Current Report
Apr 29, 2025 424B5 Filing
Apr 28, 2025 424B4 Prospectus
Apr 28, 2025 8-K Current Report
Apr 25, 2025 SCHEDULE 13G Filing
Apr 25, 2025 SCHEDULE 13G Filing
Apr 25, 2025 DEF 14A Other definitive proxy statements
Apr 25, 2025 SCHEDULE 13G/A Filing
Apr 22, 2025 8-K Current Report
Apr 22, 2025 424B4 Prospectus